Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $29.1 million.

  • Akebia Therapeutics' Net Cash Flow rose 63235.29% to $29.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $132.4 million, marking a year-over-year increase of 116092.6%. This contributed to the annual value of $9.0 million for FY2024, which is 11846.26% up from last year.
  • As of Q3 2025, Akebia Therapeutics' Net Cash Flow stood at $29.1 million, which was up 63235.29% from $23.9 million recorded in Q2 2025.
  • Akebia Therapeutics' 5-year Net Cash Flow high stood at $61.5 million for Q1 2025, and its period low was -$57.4 million during Q4 2021.
  • Over the past 5 years, Akebia Therapeutics' median Net Cash Flow value was -$3.6 million (recorded in 2023), while the average stood at -$3.3 million.
  • Per our database at Business Quant, Akebia Therapeutics' Net Cash Flow plummeted by 91993.09% in 2023 and then surged by 652727.27% in 2025.
  • Akebia Therapeutics' Net Cash Flow (Quarter) stood at -$57.4 million in 2021, then increased by 4.75% to -$54.7 million in 2022, then skyrocketed by 93.42% to -$3.6 million in 2023, then surged by 596.3% to $17.9 million in 2024, then soared by 63.19% to $29.1 million in 2025.
  • Its Net Cash Flow stands at $29.1 million for Q3 2025, versus $23.9 million for Q2 2025 and $61.5 million for Q1 2025.